Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04965842 phase 2b dose-ranging study in moderate to severe atopic dermatitis
2015-005513-72Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of abrocitinib in atopic dermatitis (AD) (5 arms), sponsored by Pfizer. Primary endpoint: Investigator's Global Assessment response at Week 12. Started Apr 2016; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2015-005513-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005513-72.